Acta Med. 2025, 68: 58-62
https://doi.org/10.14712/18059694.2025.20
Eyelid Radiotherapy-Treated Basal and Squamous Cell Carcinomas: A Case Series
References
1. DM, Hornblass A. Squamous cell carcinoma of the eyelid. Surv Ophthalmol. 1986; 30: 349–65.
<https://doi.org/10.1016/0039-6257(86)90089-5>
2. Font RL. Eyelids and lacrimal drainage system. In: Ophthalmic Pathology. An Atlas and Textbook. 3rd ed. Philadelphia, United States: WB Saunders, 1996: 2229–32.
3. J. Pathology of eyelid tumors. Indian J Ophthalmol. 2016; 64: 177–90.
<https://doi.org/10.4103/0301-4738.181752>
<PubMed>
4. JR. An actinic keratosis is neither malignant nor premalignant: It is an initiated tumor. J Am Acad Dermatol. 2003; 48: 637–8.
<https://doi.org/10.1067/mjd.2003.14>
5. BP, Thompson AH, Bishop RJ, et al. Ocular manifestations of xeroderma pigmentosum: Long‑term follow‑up highlights the role of DNA repair in protection from sun damage. Ophthalmology. 2013; 120: 1324–36.
<https://doi.org/10.1016/j.ophtha.2012.12.044>
<PubMed>
6. M, Alexandrescu C, Pirvulescu R, Gradinaru S, Costache M. Clinical. Histopathological and Therapeutical Analysis of Inferior Eyelid Basal Cell Carcinomas. J Med Life. 2014; 7: 18–22.
7. QJ, Roth KG, Warneke CL, Yin VT, El Sawy T, Esmaeli B. Impact of AJCC ‘T’ designation on risk of regional lymph node metastasis in patients with squamous carcinoma of the eyelid. Br J Ophthalmol. 2014; 98: 498–501.
<https://doi.org/10.1136/bjophthalmol-2013-304434>
8. MT, Andrew NH, O’Donnell B, McNab A, Huilgol SC, Selva D. Periocular squamous cell carcinoma: TNM staging and recurrence. Ophthalmology. 2015; 122: 1512–6.
<https://doi.org/10.1016/j.ophtha.2015.04.002>
9. K, Fargnoli MC, Kaufmann R, et al. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023. Eur J Cancer. 2023; 192: 113254.
<https://doi.org/10.1016/j.ejca.2023.113254>
10. MR, Rischin D, Schmults CD, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 Jul 26; 379: 341–351.
<https://doi.org/10.1056/NEJMoa1805131>
11. R, Solebo AL, Khandwala MA, Jones CA. Imiquimod 5% Cream as an Adjuvant Pre-operative Treatment for Basal Cell Carcinoma of the Periocular Area. Orbit. 2014; 33: 471–3.
<https://doi.org/10.3109/01676830.2014.950296>
12. Y, Takahashi S, Toshiyasu T, Tsuji H, Hanai N, Homma A. Squamous cell carcinoma of the eyelid. Jpn J Clin Oncol. 2024; 54: 4–12.
<https://doi.org/10.1093/jjco/hyad127>
<PubMed>
13. MC, Green E. Radiotherapy in Equine Practice. Vet Clin North Am Equine Pract. 2024; 40: 397–408.
<https://doi.org/10.1016/j.cveq.2024.07.005>
14. D, Ramelyte E, Dummer R, Imhof L. Radiotherapy in Periocular Cutaneous Malignancies: A Retrospective Study. Dermatology. 2019; 235: 234–9.
<https://doi.org/10.1159/000496539>
15. MN, Barnes EA, Karam I, Rembielak A. Hypofractionated Radiation Therapy in Keratinocyte Carcinoma. Clin Oncol (R Coll Radiol). 2022; 34: e218–e224.
<https://doi.org/10.1016/j.clon.2022.02.016>
16. A, Kapitanova K, Kollarova A, Sekac J. Periocular basal cell carcinoma – clinical perspectives. Oncol Rev. 2020; 14: 420.
<https://doi.org/10.4081/oncol.2020.420>
<PubMed>
17. S, De D, Kanwar AJ. Reverse koebner phenomenon in leukocytoclastic vasculitis. Indian J Dermatol. 2011; 56: 598–9.
18. B, Tan MG, Gooderham MJ, Beecker J. Reverse koebnerization of primary cutaneous follicle center lymphoma following skin biopsy. JAAD Case Rep. 2021; 16: 149–51.
<https://doi.org/10.1016/j.jdcr.2021.08.029>
<PubMed>
19. RW, Krueger GG. Response to injury of skin involved and uninvolved with psoriasis, and its relation to disease activity: Koebner and ‘reverseʼ Koebner reactions. Br J Dermatol. 1982; 106: 153–9.
<https://doi.org/10.1111/j.1365-2133.1982.tb00924.x>
20. A, Awan M, Barker CA, Bhatnagar A, Bradfield L, Brady MS, et al. Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline. Pract Radiat Oncol. 2020; 10: 8–20.
<https://doi.org/10.1016/j.prro.2019.10.014>
21. MJ, Delishaj D, Barnes EA, Bezugly A, Rembielak A. Current Role of Radiotherapy in Non-melanoma Skin Cancer. Clin Oncol (R Coll Radiol). 2019; 31: 749–58.
<https://doi.org/10.1016/j.clon.2019.08.004>
22. MN, Barnes EA, Karam I, Rembielak A. Hypofractionated Radiation Therapy in Keratinocyte Carcinoma. Clin Oncol (R Coll Radiol). 2022; 34: e218–e224.
<https://doi.org/10.1016/j.clon.2022.02.016>
23. MI, Damilakis J. LQ-based model for biological radiotherapy planning. Med Dosim. 1994; 19: 269–77.
<https://doi.org/10.1016/S0958-3947(16)30037-1>
24. J, Thomas JE, Burkhart CG. The risk of metastases from squamous cell carcinoma of the skin. Int J Dermatol. 2023; 62: 483–6.
<https://doi.org/10.1111/ijd.16164>
25. J, Thakar S, Thuro B, Esmaeli B. Prognostic Value of the Staging System for Eyelid Tumors in the 7th Edition of the American Joint Committee on Cancer Staging Manual. Ophthalmic Plast Reconstr Surg. 2017; 33: 317–24.
<https://doi.org/10.1097/IOP.0000000000000901>
26. S, Sagiv O, Rubin ML, et al. Validation Study of the AJCC Cancer Staging Manual, Eighth Edition, Staging System for Eyelid and Periocular Squamous Cell Carcinoma. JAMA Ophthalmol. 2019; 137: 537–42.
<https://doi.org/10.1001/jamaophthalmol.2019.0238>
<PubMed>
27. NG, Lee CT, Zhang E, Keith SW, Galloway TJ. Hypofractionated radiation therapy for basal and squamous cell skin cancer: A meta-analysis. Radiother Oncol. 2017; 125: 13–20.
<https://doi.org/10.1016/j.radonc.2017.08.011>
<PubMed>
28. DA, Veness MJ. Efficacy of hypofractionated radiotherapy in patients with non-melanoma skin cancer: Results of a systematic review. J Med Imaging Radiat Oncol. 2018; 62: 401–11.
<https://doi.org/10.1111/1754-9485.12718>



